AR049498A1 - Inhibidores de integrasa del virus de inmunodeficiencia humana: compuestos de pirimidinona ciclica - Google Patents
Inhibidores de integrasa del virus de inmunodeficiencia humana: compuestos de pirimidinona ciclicaInfo
- Publication number
- AR049498A1 AR049498A1 ARP050101931A ARP050101931A AR049498A1 AR 049498 A1 AR049498 A1 AR 049498A1 AR P050101931 A ARP050101931 A AR P050101931A AR P050101931 A ARP050101931 A AR P050101931A AR 049498 A1 AR049498 A1 AR 049498A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ch2ch2
- ch2n
- ch2ch2ch2
- halo
- Prior art date
Links
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010002459 HIV Integrase Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 101100203602 Hypocrea jecorina (strain QM6a) sor7 gene Proteins 0.000 abstract 1
- HMFHBZSHGGEWLO-KKQCNMDGSA-N beta-D-xylofuranose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-KKQCNMDGSA-N 0.000 abstract 1
- -1 dioxothiazinyl Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Una serie de compuestos de pirimidinona que inhiben la integrasa del VIH y con lo cual impiden la integracion viral en el ADN humano. Esta accion hace a los compuestos utiles para el tratamiento de la infeccion por el VIH y el SIDA. También productos intermediarios que son utiles para la elaboracion de los compuestos de pirimidona. Adicionalmente, están incluidas las composiciones farmacéuticas y los métodos para el tratamiento de aquellos infectados con el VIH. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en donde: R1 es (Ar1)alquilo C1-6; R2 es H, alquilo C1-6 u OR6; R3 es H, halo, hidroxi, ciano, alquilo C1-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, alquiltio C1-6, haloalcoxi C1-6, CON(R6)(R6), SOR7, SO2R7, SO2N(R6)(R6) o Ar2; R4 es H, halo, hidroxi, ciano, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 o haloalcoxi C1-6; R5 es H, halo, hidroxi, ciano, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6 o haloalcoxi C1-6; R6 es H o alquilo C1-6; R7 es alquilo C1-6; R8 y R9, tomados conjuntamente, son CH2CH2, CH2CH2CH2, CH2CH2CH2CH2, CH2CH2CH2CH2CH2, CH2CH2CH2CH2CH2CH2, OCH2CH2, CH2OCH2, OCH2CH2CH2, CH2OCH2CH2, OCH2CH2CH2CH2, CH2OCH2CH2CH2, CH2CH2OCH2CH2, OCH2CH2CH2CH2CH2, CH2OH2CH2CH2CH2, CH2CH2OH2CH2CH2, N(R6)CH2CH2, CH2N(R6)CH2, N(R6)CH2CH2CH2, CH2N(R6)CH2CH2, N(R6)CH2CH2CH2CH2, CH2N(R6)CH2CH2CH2, CH2CH2N(R6)CH2CH2, N(R6)CH2CH2CH2CH2CH2, CH2N(R6)CH2CH2CH2CH2 o CH2CH2N(R6)CH2CH2CH2; o Ar1 es un resto de formula (2); Ar2 es tetrazolilo, triazolilo, imidazolilo, pirazolilo, pirrolilo o dioxotiazinilo y es sustituido por 0-2 sustituyentes seleccionados del grupo que consiste de amino, oxo, halo, ciano y alquilo C1-6, y X-Y-Z es C(R8)(R9)CH2CH2, C(R8)(R9)CH2CH2CH2, C(R8)(R9)CH2CH2CH2CH2, C(R8)(R9)OCH2, C(R8)(R9)OCH2CH2 o C(R8)(R9)OCH2CH2CH2; o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57034804P | 2004-05-12 | 2004-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049498A1 true AR049498A1 (es) | 2006-08-09 |
Family
ID=34967012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101931A AR049498A1 (es) | 2004-05-12 | 2005-05-11 | Inhibidores de integrasa del virus de inmunodeficiencia humana: compuestos de pirimidinona ciclica |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7273859B2 (es) |
| EP (1) | EP1745052B9 (es) |
| JP (1) | JP2007537251A (es) |
| KR (1) | KR20070014173A (es) |
| CN (1) | CN1984917A (es) |
| AR (1) | AR049498A1 (es) |
| AT (1) | ATE405570T1 (es) |
| AU (1) | AU2005245789A1 (es) |
| BR (1) | BRPI0511078A (es) |
| CA (1) | CA2566755A1 (es) |
| DE (1) | DE602005009172D1 (es) |
| DK (1) | DK1745052T3 (es) |
| ES (1) | ES2310823T3 (es) |
| HR (1) | HRP20080531T3 (es) |
| IL (1) | IL179161A0 (es) |
| MX (1) | MXPA06013023A (es) |
| NO (1) | NO20065443L (es) |
| NZ (1) | NZ550698A (es) |
| PE (1) | PE20060238A1 (es) |
| PL (1) | PL1745052T3 (es) |
| PT (1) | PT1745052E (es) |
| RU (1) | RU2006143683A (es) |
| SI (1) | SI1745052T1 (es) |
| TW (1) | TW200540173A (es) |
| WO (1) | WO2005113562A1 (es) |
| ZA (1) | ZA200609181B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| WO2007059125A2 (en) * | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| WO2007058646A1 (en) * | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors: cyclic pyrimidinone compounds |
| US7902182B2 (en) * | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007064502A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide |
| US7897593B2 (en) * | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8129398B2 (en) * | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| MX2011000149A (es) * | 2008-07-02 | 2011-02-24 | Avexa Ltd | Compuestos que tienen propiedades antivirales. |
| US8431581B2 (en) * | 2008-07-02 | 2013-04-30 | Avexa Limited | Imidazopyrimidines and uses thereof |
| EA201170537A1 (ru) * | 2008-10-06 | 2011-12-30 | Мерк Шарп Энд Домэ Корп. | Ингибиторы вич-интегразы |
| US20120022045A1 (en) * | 2009-01-28 | 2012-01-26 | Shankar Venkatraman | Bridged compounds as hiv integrase inhibitors |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| EP2470014A4 (en) * | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| US9328075B2 (en) * | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| US10699038B2 (en) | 2012-03-30 | 2020-06-30 | Litmus Blue Technology LLC | Configurable representation of domain models |
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| PE20151499A1 (es) | 2012-12-21 | 2015-10-29 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico |
| WO2014104279A1 (ja) | 2012-12-27 | 2014-07-03 | 日本たばこ産業株式会社 | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途 |
| EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| ES2656696T3 (es) | 2013-05-17 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH |
| WO2014200880A1 (en) | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
| EP3252058B1 (en) | 2013-07-12 | 2021-01-20 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
| AU2014324829B2 (en) | 2013-09-27 | 2017-09-07 | Merck Sharp & Dohme Corp. | Substituted Quinolizine Derivatives useful as HIV integrase inhibitors |
| US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| US10287269B2 (en) | 2015-03-26 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors |
| KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JP2020500866A (ja) | 2016-12-02 | 2020-01-16 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物 |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9201803D0 (en) * | 1992-01-28 | 1992-03-11 | Smithkline Beecham Corp | Methods |
| UA77454C2 (en) | 2001-10-26 | 2006-12-15 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | |
| SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
| WO2004002406A2 (en) * | 2002-06-26 | 2004-01-08 | Bristol-Myers Squibb Company | Bicyclic pyrimidinones as coagulation cascade inhibitors |
| RU2329265C2 (ru) | 2002-12-27 | 2008-07-20 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа | ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US20050282839A1 (en) | 2004-01-12 | 2005-12-22 | Gilead Sciences, Inc. | Pyrimidyl phosphonate antiviral compounds and methods of use |
| US7173022B2 (en) * | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| BRPI0610030B8 (pt) * | 2005-04-28 | 2022-01-11 | Glaxosmithkline Llc | Composto, composição farmacêutica, e, uso de um composto |
-
2005
- 2005-04-20 US US11/110,589 patent/US7273859B2/en not_active Expired - Lifetime
- 2005-04-22 BR BRPI0511078-5A patent/BRPI0511078A/pt not_active IP Right Cessation
- 2005-04-22 CA CA002566755A patent/CA2566755A1/en not_active Abandoned
- 2005-04-22 CN CNA2005800236418A patent/CN1984917A/zh active Pending
- 2005-04-22 ES ES05738619T patent/ES2310823T3/es not_active Expired - Lifetime
- 2005-04-22 JP JP2007513169A patent/JP2007537251A/ja active Pending
- 2005-04-22 PL PL05738619T patent/PL1745052T3/pl unknown
- 2005-04-22 PT PT05738619T patent/PT1745052E/pt unknown
- 2005-04-22 WO PCT/US2005/013911 patent/WO2005113562A1/en not_active Ceased
- 2005-04-22 SI SI200530425T patent/SI1745052T1/sl unknown
- 2005-04-22 RU RU2006143683/04A patent/RU2006143683A/ru not_active Application Discontinuation
- 2005-04-22 MX MXPA06013023A patent/MXPA06013023A/es not_active Application Discontinuation
- 2005-04-22 AU AU2005245789A patent/AU2005245789A1/en not_active Abandoned
- 2005-04-22 DE DE602005009172T patent/DE602005009172D1/de not_active Expired - Fee Related
- 2005-04-22 DK DK05738619T patent/DK1745052T3/da active
- 2005-04-22 HR HR20080531T patent/HRP20080531T3/xx unknown
- 2005-04-22 EP EP05738619A patent/EP1745052B9/en not_active Expired - Lifetime
- 2005-04-22 KR KR1020067023555A patent/KR20070014173A/ko not_active Withdrawn
- 2005-04-22 AT AT05738619T patent/ATE405570T1/de not_active IP Right Cessation
- 2005-04-22 NZ NZ550698A patent/NZ550698A/en unknown
- 2005-05-09 TW TW094114913A patent/TW200540173A/zh unknown
- 2005-05-11 AR ARP050101931A patent/AR049498A1/es not_active Application Discontinuation
- 2005-05-11 PE PE2005000520A patent/PE20060238A1/es not_active Application Discontinuation
- 2005-11-14 US US11/273,671 patent/US7419969B2/en not_active Expired - Lifetime
-
2006
- 2006-11-03 ZA ZA200609181A patent/ZA200609181B/en unknown
- 2006-11-09 IL IL179161A patent/IL179161A0/en unknown
- 2006-11-27 NO NO20065443A patent/NO20065443L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL179161A0 (en) | 2007-03-08 |
| US20060106007A1 (en) | 2006-05-18 |
| PL1745052T3 (pl) | 2009-01-30 |
| ZA200609181B (en) | 2008-06-25 |
| EP1745052A1 (en) | 2007-01-24 |
| TW200540173A (en) | 2005-12-16 |
| NO20065443L (no) | 2006-11-27 |
| ATE405570T1 (de) | 2008-09-15 |
| CN1984917A (zh) | 2007-06-20 |
| DK1745052T3 (da) | 2009-01-05 |
| DE602005009172D1 (de) | 2008-10-02 |
| AU2005245789A1 (en) | 2005-12-01 |
| US7273859B2 (en) | 2007-09-25 |
| ES2310823T3 (es) | 2009-01-16 |
| WO2005113562A1 (en) | 2005-12-01 |
| JP2007537251A (ja) | 2007-12-20 |
| US20050256109A1 (en) | 2005-11-17 |
| US7419969B2 (en) | 2008-09-02 |
| PT1745052E (pt) | 2008-11-14 |
| EP1745052B9 (en) | 2009-10-28 |
| MXPA06013023A (es) | 2006-12-20 |
| HRP20080531T3 (en) | 2009-03-31 |
| BRPI0511078A (pt) | 2007-12-26 |
| NZ550698A (en) | 2009-05-31 |
| RU2006143683A (ru) | 2008-06-20 |
| EP1745052B1 (en) | 2008-08-20 |
| PE20060238A1 (es) | 2006-03-31 |
| KR20070014173A (ko) | 2007-01-31 |
| CA2566755A1 (en) | 2005-12-01 |
| SI1745052T1 (sl) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049498A1 (es) | Inhibidores de integrasa del virus de inmunodeficiencia humana: compuestos de pirimidinona ciclica | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR049124A1 (es) | Compuestos de de pirimidinona como inhibidores de la integrasa del virus hiv, composiciones farmaceuticas que las contienen y su uso en el tratamiento del sida y de la infeccion por hiv | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR059176A1 (es) | Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| UY28581A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| EA201000201A1 (ru) | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций | |
| AR054269A1 (es) | Derivados de 2-amido-6-amino-8-oxopurina | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| AR056317A1 (es) | Compuestos de oxindol y composicion farmaceutica | |
| PE20240886A1 (es) | Compuestos espirociclicos | |
| AR045260A1 (es) | Compuestos que contienen imidazo-oxima sustituidos | |
| AR075005A1 (es) | Derivados de sulfonamida | |
| CL2004000076A1 (es) | Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
| EA201791776A1 (ru) | Замещенные циклофаны для использования при лечении инфекции вгс | |
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| EA200701849A1 (ru) | Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |